Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Evaxion Biotech (EVAX – Research Report) today and set a price target of $18.00. The company’s shares closed last Tuesday at $5.29, close to its 52-week low of $5.16.
According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 52.8% and a 54.2% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Sensei Biotherapeutics, and Taysha Gene Therapies.
Currently, the analyst consensus on Evaxion Biotech is a Moderate Buy with an average price target of $18.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evaxion Biotech AS is an artificial intelligence immunology platform company. It uses proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market.